Current report no. 29/2025

Date of preparation: 2025-09-24

Abbreviated name of the issuer MABION S.A.

Subject: Appointment of the President of the Management Board of theCompany

Legal basis Art. 17(1) of the MAR Regulation - confidential information

Content of the report:

The Management Board of Mabion S.A. (the "Company") hereby announcesthat on September 24, 2025 the Supervisory Board of the Company adopteda resolution on the appointment of Mr. Gregor Kawaletz to the ManagementBoard of the Company for a second term of office, effective October 1,2025, entrusting him with the function of President of the ManagementBoard. The resolution of the Supervisory Board of the Company enteredinto force upon its adoption.

Mr Gregor Kawaletz graduated from the University of Cologne with amaster's degree in political science. From 2003 to 2010, he worked forNextPharma, where he held the position of Area Sales Manager and thenKey Account Director. From 2010 to 2014, he was European Sales Directorat Catalent. Between 2014 and 2020, he served as Chief CommercialOfficer at IDT-Biologika, and then from 2020 to 2021 as Chief CommercialOfficer at Albumedix. From 2021 to 2024, he worked for Recipharm AB,where he initially held the position of President of the Oral SolidDosage Division, and then Chief Commercial Officer.

Gregor Kawaletz is a seasoned commercial leader with extensive 20 yearsof experience in the CDMO sector. With a robust track record of revenuegrowth, organisational transformation, and market positioning, hecombines excellent CDMO industry insight, transactional experience, andpeople leadership to lead and create value in a CEO role. G. Kawaletz isdeeply experienced in industry trend analysis and go-to-market strategy,having successfully anticipated technology and therapeutic area trends,including oral biologics and ADCs (Antibody-Drug Conjugate). Throughouthis career, he has consistently provided strategic direction grounded inmarket intelligence and operational feasibility. He has successfullyanticipated the potential of ADCs as well as orally delivered biologics,leading internal alignment on a CAPEX plan and onboarding externalpartners, ultimately generating significant increase in revenue andprofitability in Recipharm AB and other organisations he worked for. G.Kawaletz has built relationships with multiple private equity andventure capital firms and has been trusted to lead sell-side andstrategic transformations.

According to his statement, Mr. Gregor Kawaletz does not conduct anycompetitive activity, does not participate in any competitive company asa partner in a civil law partnership, partnership, or capital company,nor does he participate in any competitive legal entity as a member ofits governing body. Mr. Gregor Kawaletz is not listed in the Register ofInsolvent Debtors maintained pursuant to the Act on the National CourtRegister.